MedTrace Logo

A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

NCT00156884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2012-01-19

No results posted yet for this study

Summary

This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.

Conditions

Interventions

DRUG

strontium-89

DRUG

cisplatin

Sponsors & Collaborators

  • The Prostate Cancer Research Foundation of Canada

    collaborator OTHER

  • Amersham Health

    collaborator INDUSTRY

  • Alberta Health services

    lead OTHER

Principal Investigators

  • Bernie Eigl, MD · Alberta Cancerboard

  • Jackson Wu · Alberta Cancerboard

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156884 on ClinicalTrials.gov